Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
MicroPort CardioFlow Medtech Corp. ( (HK:2160) ) has issued an announcement.
MicroPort CardioFlow Medtech Corp. reported a 2.7% increase in revenue for the first half of 2025, driven by a substantial rise in overseas sales and the continued global commercialization of its key products. The company also significantly reduced its net loss to RMB2.2 million, down from RMB57.8 million in the same period of 2024, due to improved operational efficiency and a gain from the deemed disposal of an equity interest in an associate.
The most recent analyst rating on (HK:2160) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on MicroPort CardioFlow Medtech Corp. stock, see the HK:2160 Stock Forecast page.
More about MicroPort CardioFlow Medtech Corp.
MicroPort CardioFlow Medtech Corp. operates in the medical technology industry, focusing on the development and commercialization of innovative cardiovascular devices. The company’s primary products include the VitaFlow Liberty® and Alwide® Plus, which have seen significant global commercialization, as well as the AnchorMan® LAAC and LAAA Systems, which are being commercialized in China and Europe.
Average Trading Volume: 12,788,390
Technical Sentiment Signal: Hold
Current Market Cap: HK$3.62B
For a thorough assessment of 2160 stock, go to TipRanks’ Stock Analysis page.